Search Tag: heparin

2023 20 Apr

Heparin-induced thrombocytopaenia (HIT) is an immune complication of heparin therapy. This review discusses the pathophysiology, incidence, clinical manifestations, diagnostic approach, and management of patients with HIT.   Pathophysiology HIT is an immune complication of heparin therapy caused by IgG antibodies to complexes of platelet...Read more

2023 21 Mar

At the #ISICEM23 this week in Brussels, the benefits and harms of therapeutic-dose heparin varied by hospitalised COVID-19 patient characteristics were discussed, and the importance of considering the heterogeneity of treatment effect (HTE) in the design and analysis of randomised clinical trials was highlighted.   To date, RCTs that have tested...Read more

2021 25 Jan

Mechanical ventilation in the ICU for 48 hours or longer is known to be associated with ARDS, which could be present either when ventilatory support is initiated or develop afterwards, typically during the first five days. ARDS affects approximately 23% of mechanically ventilated, critically ill patients and has a mortality of nearly 46%. Patients...Read more

2015 20 Jul

According to companion studies published in Academic Emergency Medicine , a lower risk treatment with rivaroxaban for blood clots was found to be more effective, less costly and enabled patients to go home the same day.  Blood clots that could potentially be fatal is a primary cause of emergency room visits each year. A large number of patients with...Read more

2015 17 Mar

According to a study published in JAMA, patients who experienced a heart attack and underwent a percutaneous coronary intervention (PCI) show a decrease in adverse clinical events when they were given anticoagulant bivalirudin following the procedure.  Compared to heparin alone or heparin plus tirofiban, bivalirudin resulted in a reduction in adverse...Read more

2015 17 Feb

According to a study published in JAMA, patients who receive fondaparinux after a certain type of heart attack had a lower risk of major bleeding events and death in the hospital and after six months as compared to patients who received low molecular weight heparin (LMWH). Both groups of patients had similar rates of subsequent heart attack or stroke....Read more

2014 07 Nov

A research team from the University of British Columbia has set out on making the use of heparin much safer by developing a universal antidote. Heparin, a lifesaving blood thinner that is used in major surgeries and treatment of heart disease, often requires an antidote to reverse its action and prevent serious bleeding issues in major surgical...Read more

2014 16 Sep

According to a study published in JAMA, there is no significant difference in the clinical and safety outcomes associated with most treatment strategies for venous thromboembolism, a common medical condition manifested as deep vein thrombosis or pulmonary embolism. Venous thromboembolism is the third leading cause of cardiovascular death....Read more